News und Analysen
EQS-News: Evotec presents sustainability strategy
EQS-News: Evotec presents sustainability strategy
EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023
EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023
EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
EQS-News: Carl Zeiss Meditec achieves double-digit growth in first half year of 2022/23 with declining earnings
EQS-News: Carl Zeiss Meditec achieves double-digit growth in first half year of 2022/23 with declining earnings
EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results
EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: Evotec SE provides update on cyber attack
EQS-News: Evotec SE provides update on cyber attack
EQS-Adhoc: Cyber Attack on Evotec
EQS-Adhoc: Cyber Attack on Evotec
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer